Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature

Respiration

Volumn 89, Issue 3, 2015, Pages 253-264

  Gläser, Sven ^a   Krüger, Stefan ^b   Merkel, Martin ^c   Bramlage, Peter ^d   Herth, Felix J F ^e  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Florence Nightingale Hospital   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d Institute für Pharmakologie und Präventive Medizin   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Inflammation; Pathophysiological relationship; Type 2 diabetes

Indexed keywords

CORTICOSTEROID;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LUNG FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; COMPLICATION; DISEASE COURSE;

DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84925235533     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000369863     Document Type: Review

References (95)

1. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN: Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2010; 24: 600-608.
2. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
3. Pamidi S, Tasali E: Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol 2012; 3: 126.
4. Zamarron C, Garcia Paz V, Morete E, del Campo Matias F: Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron Obstruct Pulmon Dis 2008; 3: 671-682.
5. McNicholas WT: Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 2009; 180: 692-700.
6. Azuma M, Chin K, Yoshimura C, Takegami M, Takahashi K, Sumi K, Nakamura T, Nakayama-Ashida Y, Minami I, Horita S, et al: Associations among chronic obstructive pulmonary disease and sleep-disordered breathing in an urban male working population in Japan. Respiration 2014; 88: 234-243.
7. Danaei G, Finucane MM, Lu Y, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
8. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL: Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract 2010; 87: 385-393.
9. Kerr EA, Heisler M, Krein SL, Kabeto M, Langa KM, Weir D, Piette JD: Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? J Gen Intern Med 2007; 22: 1635-1640.
10. Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, et al: Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107: 1376-1384.
11. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW: Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-289.
12. Parappil A, Depczynski B, Collett P, Marks GB: Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010; 15: 918-922.
13. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W: Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One 2012; 7:e43892.
14. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al: Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
15. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, Speizer FE, Barr RG, Camargo CA Jr: Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-2484.
16. Lee CT, Mao IC, Lin CH, Lin SH, Hsieh MC: Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: a nationwide population-based study. Eur J Clin Invest 2013; 43: 1113-1119.
17. Song Y, Klevak A, Manson JE, Buring JE, Liu S: Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. Diabetes Res Clin Pract 2010; 90: 365-371.
18. Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S: Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India 2013; 30: 108-112.
19. Litonjua AA, Lazarus R, Sparrow D, Demolles D, Weiss ST: Lung function in type 2 diabetes: the Normative Aging Study. Respir Med 2005; 99: 1583-1590.
20. Aparna: Pulmonary function tests in type 2 diabetics and non-diabetic people - a comparative study. J Clin Diagn Res 2013; 7: 1606-1608.
21. Dennis RJ, Maldonado D, Rojas MX, Aschner P, Rondon M, Charry L, Casas A: Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med 2010; 10: 38.
22. Lawlor DA, Ebrahim S, Smith GD: Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women's Heart and Health Study. Diabetologia 2004; 47: 195-203.
23. Lim SY, Rhee EJ, Sung KC: Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci 2010; 25: 1480-1486.
24. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM: Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004; 27: 752-757.
25. Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, Soler X, Silverman EK, Crapo J, Hokanson JE; COPDGene Investigators: Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care 2014; 37: 389-395.
26. Lange P, Parner J, Schnohr P, Jensen G: Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur Respir J 2002; 20: 1406-1412.
27. Forgiarini LA Jr, Kretzmann NA, Porawski M, Dias AS, Marroni NA: Experimental diabetes mellitus: oxidative stress and changes in lung structure. J Bras Pneumol 2009; 35: 788-791.
28. Vracko R, Thorning D, Huang TW: Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis 1979; 120: 973-983.
29. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072.
30. Andreozzi F, Succurro E, Mancuso MR, Perticone M, Sciacqua A, Perticone F, Sesti G: Metabolic and cardiovascular risk factors in subjects with impaired fasting glucose: the 100 versus 110 mg/dl threshold. Diabetes Metab Res Rev 2007; 23: 547-550.
31. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH: Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004; 64: 99-106.
32. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, Shan J, Ferrara A: Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33: 55-60.
33. Makarevich AE, Valevich VE, Pochtavtsev AU: Evaluation of pulmonary hypertension in COPD patients with diabetes. Adv Med Sci 2007; 52: 265-272.
34. Burgel PR, Escamilla R, Perez T, et al: Impact of comorbidities on COPD-specific healthrelated quality of life. Respir Med 2013; 107: 233-241.
35. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T: Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J Chron Obstruct Pulmon Dis 2014; 9: 99-105.
36. Gudmundsson G, Ulrik CS, Gislason T, Lindberg E, Brondum E, Bakke P, Janson C: Longterm survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis 2012; 7: 571-576.
37. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, Nieminen MM, Aine T, Bakke P, Janson C: Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006; 7: 109.
38. Koskela HO, Salonen PH, Niskanen L: Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease. Clin Respir J 2013; 7: 382-389.
39. Habib G, Dar-Esaif Y, Bishara H, Artul S, Badarny S, Chernin M, Jabbour A: The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation. Respir Med 2014; 108: 1641-1646.
40. Burt MG, Roberts GW, Aguilar-Loza NR, Quinn SJ, Frith PA, Stranks SN: Relationship between glycaemia and length of hospital stay during an acute exacerbation of chronic obstructive pulmonary disease. Intern Med J 2013; 43: 721-724.
41. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778.
42. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426-2432.
43. Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH: Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ 2013; 112: 244-249; quiz 250.
44. Moretti M, Cilione C, Tampieri A, Fracchia C, Marchioni A, Nava S: Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax 2000; 55: 819-825.
45. Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PM: Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 2009; 64: 857-862.
46. Singanayagam A, Schembri S, Chalmers JD: Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10: 81-89.
47. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B: Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748-1755.
48. Loukides S, Polyzogopoulos D: The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 1996; 63: 170-173.
49. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, Philips BJ, Geddes DM, Hodson ME, Baker EH: Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6: 101-109.
50. Marhoffer W, Stein M, Maeser E, Federlin K: Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15: 256-260.
51. Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, Hansen JM: Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 2014; 306:L43-L49.
52. Jones PW, Nadeau G, Small M, Adamek L: Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respir Med 2014; 108: 129-135.
53. Sode BF, Dahl M, Nordestgaard BG: Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011; 32: 2365-2375.
54. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE: Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
55. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010; 80: 112-119.
56. Lazarus R, Sparrow D, Weiss ST: Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. Eur Respir J 1998; 12: 641-645.
57. Engstrom G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L: Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J Intern Med 2003; 253: 574-581.
58. Engstrom G, Janzon L: Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet Med 2002; 19: 167-170.
59. Eriksson KF, Lindgarde F: Poor physical fitness, and impaired early insulin response but late hyperinsulinaemia, as predictors of NIDDM in middle-aged Swedish men. Diabetologia 1996; 39: 573-579.
60. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Brancati FL: Vital capacity as a predictor of incident type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 1472-1479.
61. Kwon CH, Rhee EJ, Song JU, Kim JT, Kwag HJ, Sung KC: Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men. Cardiovasc Diabetol 2012; 11: 38.
62. Heianza Y, Arase Y, Tsuji H, Saito K, Amakawa K, Hsieh SD, Kodama S, Shimano H, Yamada N, Hara S, Sone H: Low lung function and risk of type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 9 (TOPICS 9). Mayo Clin Proc 2012; 87: 853-861.
63. Ford ES, Mannino DM, National H: Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study. Diabetes Care 2004; 27: 2966-2970.
64. Wannamethee SG, Shaper AG, Rumley A, Sattar N, Whincup PH, Thomas MC, Lowe GD: Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care 2010; 33: 1990-1996.
65. Joo H, Park J, Lee SD, Oh YM: Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. J Korean Med Sci 2012; 27: 901-906.
66. Park SK, Larson JL: The relationship between physical activity and metabolic syndrome in people with chronic obstructive pulmonary disease. J Cardiovasc Nurs 2014; 29: 499-507.
67. Shah S: Frequency of Metabolic syndrome and its relationship with systemic inflammation in patients of chronic obstructive pulmonary disease (COPD) in ethnic Kashmiri population of India. Chest 2014; 145: 400A.
68. Akpinar EE, Akpinar S, Ertek S, Sayin E, Gulhan M: Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks 2012; 60: 230-237.
69. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999; 353: 1649-1652.
70. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384-2389.
71. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, Luzio SD, Owens DR, Shale DJ: Insulin resistance and inflammation - a further systemic complication of COPD. COPD 2007; 4: 121-126.
72. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52: 1799-1805.
73. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
74. Takenaka S, Kawayama T, Imaoka H, Sakazaki Y, Oda H, Kaku Y, Matsuoka M, Okamoto M, Kato S, Yamada K, Hoshino T: The progression of comorbidity in IL-18 transgenic chronic obstructive pulmonary disease mice model. Biochem Biophys Res Commun 2014; 445: 597-601.
75. Bayliss EA, Blatchford PJ, Newcomer SR, Steiner JF, Fairclough DL: The effect of incident cancer, depression and pulmonary disease exacerbations on type 2 diabetes control. J Gen Intern Med 2011; 26: 575-581.
76. Groenewegen KH, Schols AM, Wouters EF: Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459-467.
77. Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE: Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care 2013; 36: 3009-3014.
78. Slatore CG, Bryson CL, Au DH: The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009; 122: 472-478.
79. Suissa S, Kezouh A, Ernst P: Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
80. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947.
81. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN: Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789-1796.
82. Blackburn D, Hux J, Mamdani M: Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17: 717-720.
83. Dendukuri N, Blais L, LeLorier J: Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol 2002; 54: 59-64.
84. O'Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, Carlsson LG, Sin DD: Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012; 106: 1487-1493.
85. Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; CD001288.
86. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, et al: Short-term vs. conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309: 2223-2231.
87. Ceviker Y, Sayiner A: Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther 2014; 27: 179-183.
88. Cheng T, Gong Y, Guo Y, Cheng Q, Zhou M, Shi G, Wan H: Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin Respir J 2013; 7: 305-318.
89. Anton E: How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med 2013; 7: 25-32.
90. Piatti P, Setola E, Galluccio E, Costa S, Fontana B, Stuccillo M, Crippa V, Cappelletti A, Margonato A, Bosi E, Monti LD: Smoking is associated with impaired glucose regulation and a decrease in insulin sensitivity and the disposition index in first-degree relatives of type 2 diabetes subjects independently of the presence of metabolic syndrome. Acta Diabetol 2014; 51: 793-799.
91. Drozdovszky O, Barta I, Antus B: Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease. Respiration 2014; 87: 408-415.
92. Grubek-Jaworska H, Paplinska M, Hermanowicz-Salamon J, Bialek-Gosk K, Dabrowska M, Grabczak E, Domagala-Kulawik J, Stepien J, Chazan R: IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration 2012; 84: 101-107.
93. Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, et al: Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201-2210.
94. Archer JR, Misra S, Simmgen M, Jones PW, Baker EH: Phase II study of tight glycaemic control in COPD patients with exacerbations admitted to the acute medical unit. BMJ Open 2011; 1:e000210.
95. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H: Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(suppl 2): S14-S21.